Carrié C, Bardonneau G, Petit L, et al. - Among critically ill patients who received third-generation cephalosporins (3GCs) or piperacillin-tazobactam (PTZ) for wild-type AmpC-producing Enterobacterales pulmonary infections, researchers compared the rate of therapeutic failure. The participants were retrospectively included. They compared two groups of patients based on the definitive antibiotic therapy (3GCs or PTZ) considered following < 48 h of empirical antibiotic treatment. Higher rates of therapeutic failure were reported in relation to the use of 3GCs in the propensity score-matched population. Experts identified no link between secondary de-escalation to 3GCs following 48 h of PTZ as first-line antibiotic treatment and increased rate of emergence of resistance. Overall, the recommendation of avoiding 3GCs as first-line antibiotic therapy in wild-type AmpC-producing Enterobacterales pulmonary infections was, ultimately, confirmed in this study.